Skip to main content
. 2025 Apr 10;2025:2702089. doi: 10.1155/cjgh/2702089

Figure 3.

Figure 3

Primary endpoint; the percentage of patients with decreased erosion of more than 50%. (a) FAS. A: CKD-495 75 mg vs. placebo (p=0.0040), B: CKD-495 75 mg vs. Stillen 60 mg (p=0.0298), C: CKD-495 75 mg vs. Rebamipide 100 mg (p=0.0116), D: CKD-495 150 mg vs. Placebo (p=0.7164), E: CKD-495 150 mg vs. Stillen 60 mg (p=0.2832), F: CKD-495 150 mg vs. Rebamipide 100 mg (p=0.5311). (b) PPS. A: CKD-495 75 mg vs. placebo (p=0.0026), B: CKD-495 75 mg vs. Stillen 60 mg (p=0.0182), C: CKD-495 75 mg vs. Rebamipide 100 mg (p=0.0165), D: CKD-495 150 mg vs. Placebo (p=0.4587), E: CKD-495 150 mg vs. Stillen 60 mg (p=0.1786), F: CKD-495 150 mg vs. Rebamipide 100 mg (p=0.2289).